SebastianMartinek Ph.D.

Partner

Boston + 1.617.449.6888

Connect

Share

Dr. Sebastian Martinek focuses his practice on the development and management of global patent portfolios involving pharmaceutical and biotechnology innovations and medical devices. He guides clients from the early stages of patent portfolio development, through the product development process, to the development of late-stage life cycle management strategies and regulatory extension opportunities.

Sebastian regularly analyzes third-party patent portfolios and advises clients with such transactions. He provided patent advice to Celgene Corporation in its acquisition of Receptos for $7.2 billion and its global license agreement with Nogra Pharma Limited with an upfront payment of $710 million. Other representative clients include Akebia Therapeutics, Chromocell Corporation, Hookipa Biotech AG, Follica, the Icahn School of Medicine at Mount Sinai, REGENXBIO, and Versant Venture Management.

Sebastian holds a Ph.D. in genetics and has experience in numerous technologies such as microbiome-related technologies, vaccines, small molecules, antibodies, protein- and peptide-based therapeutics, protein glycosylation, antisense-based therapeutics, RNAi, and gene therapies.

Erfahrung

  • Royalty Pharma acquires EMGALITY® royalty from Arteaus Therapeutics for $260 millionJones Day advised Royalty Pharma, the industry leader in acquiring pharmaceutical royalties, in its $260 million acquisition of the royalty interest held by Arteaus Therapeutics, LLC on future global net sales of Eli Lilly and Company’s EMGALITY® (galcanezumab), an anti-CGRP antibody for the prevention of migraine.
  • Hookipa Pharma completes $84 million IPOJones Day served as IP counsel in connection with the $84 million initial public offering of Hookipa Pharma Inc. (NASDAQ: HOOK).
  • GlycoVaxyn builds bioconjugate vaccine patent portfolioJones Day represents GlycoVaxyn AG in developing its patent portfolio and prosecution strategies relating to next-generation bioconjugate vaccines, including methods for production of the vaccines using in vivo systems.
  • Mount Sinai School of Medicine enforces patent on key biotech pharmaceutical productJones Day represented Mount Sinai School of Medicine of New York University in a multinational cross-jurisdictional patent infringement litigation against a global pharmaceutical company.
  • Hookipa Biotech develops worldwide patent portfolioJones Day assists Hookipa Biotech AG in the development of a worldwide patent portfolio.
  • Celgene acquires Triphase Accelerator's first compound, MarizomibJones Day advised Celgene Corporation in the acquisition, through an affiliate, of Triphase Accelerator Corporation's assets related to its proteasome inhibitor, marizomib (MRZ), which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Shiseido acquires Olivo LaboratoriesJones Day advised Shiseido Americas Corporation, a subsidiary of Shiseido Co., Ltd., a leading global cosmetics company, in connection with the acquisition of substantially all of the assets of Olivo Laboratories, LLC, a startup advancing the dermatological field through proprietary biomaterials technology.
  • Dainippon Sumitomo Pharma acquires oncology-focused biotechnology company Boston Biomedical for $200 million plus up to $2.2 billion in earnoutsJones Day advised Dainippon Sumitomo Pharma Co. in its acquisition of Boston Biomedical Inc. ("BBI") for US$200 million plus up to US$2.2 billion in earnouts.
    •

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.